In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.
Feature|Articles|July 21, 2026
The Hidden Cost of the Beautiful Game: Part 2
Fact checked by: Marco Meglio, Kelly King
From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.
Advertisement
Advertisement
One effort to better understand that longer timeline is underway in London, England, where researchers with the Advanced Brain Health Clinic are studying retired soccer and rugby players through a combination of clinical care and longitudinal research. Caleigh Lynch, MSc, a research technician with the Advanced Brain Health Clinic, and Thomas Parker, PhD, a consultant neurologist and clinical lecturer at Imperial College London, are among the researchers involved in the project.
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
Advertisement
Advertisement